AZD0156 (AstraZeneca) is an oral, ATP–competitive ATM inhibitor that showed strong synergy with PARPi and topoisomerase (TOP)–I inhibitors in BRCA–mutated xenografts and sensitized TP53–deficient lung–cancer cell lines to radiation [22, 23]. The gene discussed is TP53; the disease is cancer.